Monsun

Monsun is a Danish biotechnology company dedicated to revolutionizing the administration of biologics through its proprietary oral delivery platform. Founded in 2023 and headquartered in Copenhagen, the company focuses on engineering advanced formulations that protect peptides and proteins from the harsh environment of the gastrointestinal tract while facilitating their transport across the intestinal barrier. This technology aims to convert currently injectable-only therapies into patient-friendly oral tablets, significantly improving treatment adherence and quality of life for patients with chronic conditions. Monsun is currently in the pre-clinical stage, leveraging its platform to develop a pipeline of oral versions of high-value therapeutic molecules, with an initial focus on metabolic diseases such as obesity and diabetes. The company is a portfolio member of the BioInnovation Institute (BII), benefiting from the region's strong expertise in metabolic disease research.